Cardiovascular: clinical-trial pipeline
68,248 cardiovascular trials are in ClinicalTrials.gov and the EU CTIS portal; 14,645 are not yet finished and 939 of those are in phase 2/3 or 3. Source: Arcadium Data, data as of .
Open trials by phase
| Phase | Trials |
|---|---|
| Not applicable | 11,636 |
| Phase 3 | 812 |
| Phase 4 | 775 |
| Phase 2 | 728 |
| Phase 1 | 267 |
| Phase 1/2 | 182 |
| Phase 2/3 | 127 |
| Early phase 1 | 118 |
Sponsors with the most open trials
Recently changed open trials
| Registry id | Title | Sponsor | Phase | Status | Countries |
|---|---|---|---|---|---|
| NCT06200207 | A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure a… | Novo Nordisk A/S | Phase 3 | Active, not recruiting | Argentina, Australia, Bulgaria, Canada +11 |
| NCT05062239 | Post-Operative Atrial Fibrillation After Surgical Aortic Valve Replacement and the Influence of Statins | Odense University Hospital | Not applicable | Recruiting | Denmark |
| NCT04576156 | A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk M… | Geron Corporation | Phase 3 | Active, not recruiting | Argentina, Austria, Australia, Belgium +21 |
| 2023-508904-39-00 | Rivaroxaban Monotherapy and CYP2C19 Genotype Testing in Patients with Atrial Fibrillation and Percutaneous Co… | Amsterdam UMC | Phase 4 | Active, not recruiting | Netherlands |
| NCT06079879 | A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essen… | Merck Sharp & Dohme LLC | Phase 3 | Active, not recruiting | Argentina, Australia, Belgium, Canada +19 |
| NCT06016738 | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | Olema Pharmaceuticals, Inc. | Phase 3 | Active, not recruiting | Argentina, Austria, Australia, Belgium +22 |
| 2023-510213-25-01 | Beta-Blockers in Takotsubo Syndrome: A Randomized Clinical Trial | Fundacion Casa Del Corazon | Phase 4 | Recruiting | Spain |
| 2023-509804-14-00 | The role of meldonium and individualized physical activities in the treatment of patients with heart failure | Pauls Stradins Clinical University Hospital | Phase 4 | Not yet recruiting | Latvia |
| 2023-508208-40-00 | Short versus long antiplatelet therapy after TAVI | Centre Hospitalier Universitaire De Caen Normandie | Phase 2/3 | Recruiting | France |
| 2023-506299-28-00 | Effect of nonsteroidal anti-inflammatory drugs in the management of postoperative pain after cardiac surgery:… | Centre Hospitalier Universitaire Amiens Picardie | Phase 4 | Recruiting | France |
| NCT05284747 | EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction | Amgen | Phase 4 | Active, not recruiting | Brazil, Sweden, United States |
| NCT04319627 | Statins for Venous Event Reduction in Patients With Venous Thromboembolism | Ottawa Hospital Research Institute | Phase 3 | Recruiting | Canada, France, United Kingdom, Ireland +2 |
| 2023-510362-26-00 | Carvedilol vs. flecainida clinical trial in idiopathic ventricular arrhythmias. | Fundacion Instituto De Investigacion Sanitaria De Santiago De Compostela | Phase 4 | Recruiting | Spain |
| NCT06523959 | Avoiding Risks of Thrombosis and Bleeding in Surgery (ARTS) Trial | Clinical Urology and Epidemiology Working Group | Phase 4 | Recruiting | Finland |
| NCT06195540 | RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing | University Hospital, Angers | Phase 3 | Recruiting | France |
| NCT06166654 | Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload | Region Hovedstaden | Phase 4 | Recruiting | Denmark |
| NCT06122779 | Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failu… | Bristol-Myers Squibb | Phase 2 | Active, not recruiting | Argentina, Canada, China, Spain +7 |
| NCT05879276 | Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitaliz… | Central Hospital, Nancy, France | Phase 3 | Recruiting | France |
| 2023-508183-29-00 | Effect of Roxadustat on Cardiometabolism | Pohjois-Pohjanmaan hyvinvointialue | Phase 4 | Active, not recruiting | Finland |
| 2023-506669-70-00 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safet… | Alexion Pharmaceuticals Inc. | Phase 3 | Active, not recruiting | Austria, Belgium, Czechia, Germany +10 |
All areas: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Cardiovascular clinical trials: 14,645 open, 939 in phase 3", https://arcadiumdata.io/clinical-trials/area/cardiovascular/, data as of 2026-10-25.